4571.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 02:59):

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan...

Stats
Dagens volum	61 600.00
Gjennomsnittsvolum	548 923
Markedsverdi	12.74B
EPS	¥0 ( 2024-02-13 )
Neste inntjeningsdato	( ¥0 ) 2024-05-10
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-12.12
ATR14	¥0.740 (0.41%)

Volum Korrelasjon

Lang: 0.19 (neutral)

Kort: 0.26 (neutral)

Signal:(46.526) Neutral

NanoCarrier Co., Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

NanoCarrier Co., Ltd. Korrelasjon - Valuta/Råvare

-0.05
( neutral )

-0.03
( neutral )

-0.25
( neutral )

-0.04
( neutral )

0.40
( neutral )

0.26
( neutral )

NanoCarrier Co., Ltd. Økonomi

Annual	2022
Omsetning:	¥202.19M
Bruttogevinst:	¥159.60M (78.94 %)
EPS:	¥-18.70

FY	2022
Omsetning:	¥202.19M
Bruttogevinst:	¥159.60M (78.94 %)
EPS:	¥-18.70

FY	2022
Omsetning:	¥264.03M
Bruttogevinst:	¥222.74M (84.36 %)
EPS:	¥-26.90

FY	2021
Omsetning:	¥313.26M
Bruttogevinst:	¥274.90M (87.75 %)
EPS:	¥-41.53

Financial Reports:

No articles found.

NanoCarrier Co., Ltd.

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.